← Back to all grants

DoW Peer Reviewed Cancer, Clinical Trial Award

Funding
See details
Status
Closing soon
Deadline
October 5, 2026 (23 days left)
Agency
Scope
Nationwide
Source
Grants.gov
Est. $45M total
October 5, 2026 (23 days left)
Nationwide

Description

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations. Distinctive Features: • Applications to this award mechanism must include a clinical trial. • Projects can range from phase 0 to phase III. • If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial. • Applications are required to include patient advocates. • Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.

Eligibility

See official grant page for eligibility requirements

Industry Tags

Healthcare

About This Grant

Summary: The fiscal year 2026 (FY26) Peer Reviewed Cancer Research Program (PRCRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of cancer within at least one of the FY26 PRCRP Topic Areas. Clinical trials proposed may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) that evaluate the effects of interventions or inform the design of more advanced trials to large-scale trials (up to phase III) to determine efficacy in relevant patient populations. Distinctive Features: • Applications to this award mechanism must include a clinical trial. • Projects can range from phase 0 to phase III. • If an Investigational New Drug (IND) application, Investigational Device Exemption (IDE), or equivalent, is required, a regulatory application must be submitted to the relevant regulatory agency by the Clinical Trial Award application submission deadline. The regulatory application should be specific to the product and indication to be tested in the proposed clinical trial. • Applications are required to include patient advocates. • Animal studies are NOT allowed under this award mechanism. All preclinical work must be completed prior to the award start date.

Funding Information

Estimated Total Program Funding
$45,000,000
Expected Number of Awards
10

Eligibility Overview

This opportunity from Defense Health Agency Contracting Activity - DHACA is open to eligible applicants nationwide. Organizations working in Healthcare are especially encouraged to review the requirements.

Federal grant opportunities like this one are typically open to a range of applicant types. Common eligible organizations include:

  • Nonprofits and 501(c)(3) organizations
  • Small businesses and startups (especially for SBIR/STTR programs)
  • State, local, and tribal governments
  • Colleges, universities, and research institutions
  • Individuals (for select programs in education, arts, and research)

Eligibility requirements vary by opportunity. Always review the official listing before investing time in an application.

How to Apply

  1. 1

    Review the full opportunity

    Read the complete Notice of Funding Opportunity (NOFO) for this Defense Health Agency Contracting Activity - DHACA program on its official page (https://www.grants.gov/search-results-detail/362268).

  2. 2

    Confirm eligibility

    Check that your organization meets every requirement set by Defense Health Agency Contracting Activity - DHACA — applicant type, location, registration status, and any prior-award restrictions.

  3. 3

    Prepare required documents

    Gather your budget narrative, needs statement, organizational details, SAM.gov registration, and any required certifications.

  4. 4

    Submit before the deadline

    This opportunity closes on October 5, 2026. Submit at least 48 hours early — portal systems are often slow near closing time.

Grant Writing Tips

Proposals for healthcare programs such as those from Defense Health Agency Contracting Activity - DHACA are competitive — these tips can strengthen your application:

  • Start your application at least 4 weeks before the deadline — rushed proposals score lower.
  • Tailor your needs statement to match the funder's stated priorities, using their exact language where possible.
  • Have a colleague outside your team review your budget narrative before submitting — fresh eyes catch errors reviewers penalize.

More Grants from Defense Health Agency Contracting Activity - DHACA

Frequently Asked Questions

Who is eligible for DoW Peer Reviewed Cancer, Clinical Trial Award?

This opportunity from Defense Health Agency Contracting Activity - DHACA is open to eligible applicants nationwide. Organizations working in Healthcare are especially encouraged to review the requirements. Always confirm the full eligibility criteria on the official listing before applying.

How much funding does DoW Peer Reviewed Cancer, Clinical Trial Award provide?

The total estimated program funding for DoW Peer Reviewed Cancer, Clinical Trial Award is $45,000,000.

When is the deadline for DoW Peer Reviewed Cancer, Clinical Trial Award?

The application deadline for DoW Peer Reviewed Cancer, Clinical Trial Award is October 5, 2026. Submit at least 48 hours early to avoid last-minute portal issues.

How do I apply for DoW Peer Reviewed Cancer, Clinical Trial Award?

Apply for DoW Peer Reviewed Cancer, Clinical Trial Award through the official grant page (https://www.grants.gov/search-results-detail/362268). Confirm your eligibility and prepare your application materials before the deadline.

Helpful Resources

✍️Grant Writing Help

Need help writing your grant application?

Try Instrumentl — Grant Writing Software →
🏢Start Your Business

Need to form an LLC or corporation first?

Form your business with ZenBusiness →
🤝Nonprofit Formation

Starting a nonprofit to apply for grants?

Launch your nonprofit with Swyft Filings →
📊Grant Management

Track and manage multiple grant applications?

Try Bloomerang for nonprofits →

GrantLocate may earn a commission from qualifying purchases. This does not affect our grant listings.

Related Grants